A research alliance of Heidelberg University Hospital and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), jointly with colleagues of the Helmholtz Center for Environmental Research in Leipzig, have discovered a new metabolic pathway which makes malignant brain tumors (gliomas) more aggressive and weakens patients’ immune systems. Using drugs to inhibit this metabolic pathway is a new approach in cancer treatment. The group’s results have been published in the prestigious specialist journal Nature.
In brain tumor tissue, it is possible to detect both the enzyme TDO (red) and the dioxin receptor AHR (brown) in the same regions. (Staining: Felix Sahm, Neuropathology Dept., Heidelberg University Hospitals. Picture: “Nature”).
Glioma is the most frequent and most malignant brain tumor in adults. In Germany, about 4,500 people are newly diagnosed with glioma every year. About 75 percent of such tumors are considered particularly aggressive with an average life expectancy of eight months to two years. The standard treatment is surgery to remove the tumor as completely as possible, followed by radiotherapy, usually in combination with chemotherapy. However, results are unsatisfactory, because these tumors are very resilient and soon start growing back. Therefore, there is an urgent need for new treatment approaches.
Tumors grow more aggressively and immune system is weakened
The Helmholtz Junior Research Group “Experimental Neuroimmunology” led by Professor Dr. Michael Platten of DKFZ and the Department of Neurooncology of Heidelberg University Hospital and the National Center for Tumor Diseases (NCT) headed by Professor Dr. Wolfgang Wick have come across the kynurenin molecule in their studies of human cancer cells and in the mouse model. Kynurenin is formed when the amino acid tryptophan – a protein component taken in with food – is broken down in the body. “We have been able to detect increased levels of kynurenin in cancer cells of glioma patients with particularly aggressive tumors,” Professor Michael Platten explained. The current research results from Heidelberg show that this link also appears to exist in other types of cancer such as cancers of the bladder, bowel or lungs.
It was even more astonishing for the investigators to find that kynurenin activates a protein known as dioxin receptor. This, in turn, triggers a cascade of chemical reactions which ultimately promote tumor growth and weaken the immune system. So far, it had only been known that the dioxin receptor, scientifically called aryl hydrocarbon receptor (AHR), is activated by environmental toxins. “Why this receptor is even present in body cells and which is its activation partner in the body, was yet unknown,” says Dr. Christiane Opitz, first author of the research article. “Kynurenin seems to have very similar effects as dioxin, but it is formed by the body itself,” said Professor Platten.
Yet another new discovery was presented by the group: The amino acid tryptophan was broken down in cancer cells by a specific enzyme called tryptophan dioxygenase, or TDO for short, which scientists had previously found primarily in liver cells. “It came as a surprise to us that TDO is also active in cancer cells and strongly so in particularly aggressive tumors.”
Searching for substances to specifically inhibit this metabolic pathway
The newly discovered metabolic pathway is a potential target for cancer treatment. The intention is to inhibit tumor growth and strengthen the immune system. “We will start searching for substances that specifically inhibit this metabolic pathway and may be used as potential antitumor drugs,” said Professor Wolfgang Wick envisioning the next steps ahead.Literature:
Heidelberg University Hospital and Medical Faculty of Heidelberg University Patient Care, Research and Teaching of International Standing Heidelberg University Hospital is among the largest and most renowned medical centers in Germany. The Medical Faculty of Heidelberg University ranges among the internationally relevant biomedical research institutes in Europe. The common goal is to develop new therapies and to apply them rapidly for the benefit of the patient. Hospitals and Faculty have approximately 10,000 employees and are active in training and qualification. In more than 50 departments, clinics and special departments with about 2,000 hospital beds, approximately 550,000 patients receive inpatient and outpatient treatment each year. There are currently about 3,600 aspiring doctors studying medicine in Heidelberg; the Heidelberg Curriculum Medicinale (HeiCuMed) is at the top of medical teaching and training in Germany.
Further reports about: > Cancer > DKFZ > Dioxin-like > German language > Germany > Nature Immunology > Public Relations > aggressive > amino acid > amino acid tryptophan > biomedical research > brain tumor > cancer cells > chemical engineering > chemical reaction > environmental toxin > immune system > malignant brain tumor > medical research > risk factor > tumor growth
Fingerprint' technique spots frog populations at risk from pollution
27.03.2017 | Lancaster University
Parallel computation provides deeper insight into brain function
27.03.2017 | Okinawa Institute of Science and Technology (OIST) Graduate University
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
27.03.2017 | Earth Sciences
27.03.2017 | Life Sciences
27.03.2017 | Life Sciences